强生多发性骨髓瘤联合疗法取得“显著”成果

Group 1 - Johnson & Johnson (JNJ) shares rose by 1.7% following a report indicating that Tecvayli combined with Darzalex reduces the risk of disease progression or death by 83% compared to standard treatment options [1][2] - The report suggests that this combination therapy may support earlier line usage as treatment paradigms evolve [1][2] - The collaboration partner for Carvykti, Legend Biotech (LEGN), is also gaining attention in light of these developments [1][2]